Rapid Testing Cuts Time to Antibiotics for Pneumonia
A clinical trial found that rapid molecular pathogen testing significantly reduces the time required to provide appropriate antibiotic treatment for pneumonia patients. Patients receiving the rapid test received targeted therapy in 7 hours compared to 72 hours for those in the standard care group.
Why it matters
Faster diagnostic testing can drastically improve outcomes for critically ill patients and help combat antibiotic resistance.
Rapid molecular pathogen testing could substantially accelerate appropriate antibiotic treatment for critically ill patients with suspected pneumonia, according to findings from the IRISPAT-1 randomised controlled feasibility trial.
The study evaluated whether multiplex polymerase chain reaction (mPCR) testing could improve antimicrobial decision-making in mechanically ventilated adults with suspected pneumonia. Although molecular panels can rapidly identify respiratory pathogens, evidence supporting their impact on antimicrobial therapy in critical care remains limited.
Researchers enrolled 40 mechanically ventilated patients with suspected pneumonia between July 2024 and October 2025. All participants had started new antibiotic treatment within 24 hours and were randomly assigned to receive either standard care or testing with the BioFire FilmArray Pneumonia Panel alongside standard care.
The primary outcome was the time taken for patients to receive appropriate antimicrobial therapy.
Patients undergoing rapid mPCR testing received appropriate antibiotic therapy considerably sooner than those receiving standard care.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in